Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours / Ramundo, V., Del Prete, M., Marotta, V., Marciello, F., Camera, L., Napolitano, V., De Luca, L., Circelli, L., Colantuoni, V., Di Sarno, A., Carratù, A.C., de Luca di Roseto, C., Colao, A., Faggiano, A.. - In: CLINICAL ENDOCRINOLOGY. - ISSN 1365-2265. - 80:6(2014), pp. 850-855. [10.1111/cen.12411]
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours
Ramundo, V
Writing – Original Draft Preparation
;Faggiano, A
2014
Abstract
Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).| File | Dimensione | Formato | |
|---|---|---|---|
|
Faggiano_Impact-of-ocreotide.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
152.88 kB
Formato
Adobe PDF
|
152.88 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
